| Donor, n (%) | GVHD, n (%) | ||
|---|---|---|---|
| MSD | 11 (20.4) | Acute | 19 (35.2) |
| MUD | 21 (38.9) | Grade 2-4 | 11 (20.4) |
| MMUD | 12 (22.2) | Chronic | 10 (18.5) |
| Haploidentical | 10 (18.5) | Moderate-severe | 2 (3.8) |
| GVHD prophylaxis, n (%) | Active immunosuppression, n (%) | 40 (74.1) | |
| PTCy-based | 36 (66.7) | Ongoing prophylaxis | 27 (50) |
| Sirolimus-Tacrolimus | 12 (22.2) | Corticosteroids | 7 (13) |
| Other | 6 (11.1) | Second-line treatment | 6 (11.1) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.